Resolving the atomic level activation mechanisms of lecithin-cholesterol acyltransferase-targeted therapeutic agents utilising a novel combination of modern computational and experimental techniques

Bidragets beskrivning

Lecithin-cholesterol acyltransferase (LCAT) is one of the key enzymes in the metabolism of high-density lipoproteins (HDLs). This research project resolves the unclear activation mechanism of LCAT enzyme by utilizing therapeutic HDL-mimicking nanodiscs and small positive allosteric modulators. The study combines in a new way the state-of-the-art computational and experimental methods to achieve an atomistic description of how LCAT enzyme interacts with its activating HDL-mimetic nanodiscs and positive allosteric modulators, and how these therapeutics mechanistically activate LCAT. In addition, the mechanistic insights acquired during the project will be translated to more potent in vivo properties. The results contribute to the development of new therapeutic agents against dyslipidemic conditions. In addition, it provides a new computational and experimental platform for studying the structure and function of therapeutic nanodiscs in different contexts.
Visa mer

Startår

2022

Slutår

2027

Beviljade finansiering

Artturi Koivuniemi Orcid -palvelun logo
447 650 €

Andra beslut

372121
Akademiforskarens forskningskostnader(2025)
200 000 €
353815
Akademiforskarens forskningskostnader(2022)
300 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Beslutfattare

Forskningsrådet för biovetenskap, hälsa och miljö
30.05.2022

Övriga uppgifter

Finansieringsbeslutets nummer

350636

Vetenskapsområden

Farmaci

Forskningsområden

Farmasia

Identifierade teman

pharmacy, biomedicine